TearLab to Participate in the Canaccord Genuity 33rd Annual Growth Conference
07 Août 2013 - 2:55PM
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the
"Company") announced today that its Chief Executive Officer, Elias
Vamvakas, will present an update on the Company's business at the
Canaccord Genuity 33rd Annual Growth Conference on Wednesday,
August 14, 2013 at 11:00 a.m. Eastern Time. The conference will be
held at the Intercontinental Boston Hotel in Boston, MA.
Mr. Vamvakas' presentation will be webcast live and archived for
at least 90 days on the Company's website at http://www.tearlab.com
under the "Webcasts" tab in the Investors section.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets
lab-on-a-chip technologies that enable eye care practitioners to
improve standard of care by objectively and quantitatively testing
for disease markers in tears at the point-of-care. The TearLab®
Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay
developed for the award-winning TearLab Osmolarity
System. Headquartered in San Diego, CA, TearLab Corporation's
common shares trade on the NASDAQ Capital Market under the symbol
'TEAR' and on the Toronto Stock Exchange under the symbol
'TLB'.
Forward-Looking Statements
This press release may contain forward-looking
statements. These statements relate to future events and are
subject to risks, uncertainties and assumptions about TearLab.
Examples of forward-looking statements in this press release
include statements regarding the future potential of the TearLab
Osmolarity System and the related impact on our sales. These
statements are only predictions based on our current expectations
and projections about future events. You should not place
undue reliance on these statements. Actual events or results may
differ materially. Many factors may cause our actual results
to differ materially from any forward-looking statement, including
the factors detailed in our filings with the Securities and
Exchange Commission and Canadian securities regulatory authorities,
including but not limited to our annual and quarterly reports on
Forms 10-K and 10-Q. We do not undertake to update any
forward-looking statements.
CONTACT: Stephen Kilmer
(647) 872-4849
skilmer@tearlab.com
Talbots (NYSE:TLB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Talbots (NYSE:TLB)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
Real-Time news about Talbots (The) (New York Stock Exchange): 0 recent articles
Plus d'articles sur